華興資本控股(01911.HK)正就審計業績考慮替代方案 續停牌
華興資本控股(01911.HK)公布,核數師在聯繫公司主席、行政總裁及控股股東包凡、並向其了解今年2月公告披露事項前,無法完成審計工作,目前有關要求仍未得到滿足,但公司一直積極考慮其他替代方案,以盡刊發截至2022年12月31日止年度的經審計財務報表,並且已經就該方案取得重要進展。公司將在計劃最終確定、並獲得批准後,適時作出進一步公告。
公司的主要業務為提供投資銀行及投資管理服務。自今年4月3日股份暫停買賣,業務及營運維持正常。
此外,於昨日(2日)公司執行董事兼聯合創始人謝屹璟被任命為代理首席執行官,以優化執行委員會的決策流程及提高業務營運效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.